EUCTR2011-002789-18-DE
进行中（未招募）
不适用
A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION - RAFFAELLO
Menarini Ricerche S.p.A0 个研究点目标入组 240 人2011年8月8日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- ON-PERMANENT ATRIAL FIBRILLATION
- 发起方
- Menarini Ricerche S.p.A
- 入组人数
- 240
- 状态
- 进行中（未招募）
- 最后更新
- 11年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Male or female patients 18 years and older;
- •2\. Patients with persistent AF suitable for electrical direct current
- •cardioversion (DCC);
- •NOTE: According to the ESC classification, persistent AF is defined as a
- •continuous AF with a minimum duration of 7 days or requiring
- •termination by cardioversion. Prior to randomisation, successful
- •electrical cardioversion and maintenance of sinus rhythm at 2 hours
- •shall be documented;
- •3\. A female of childbearing potential may be enrolled providing she:
- •\- has a negative pregnancy test at baseline and
排除标准
- •1\. Patients with first diagnosed AF (namely first onset of AF irrespective
- •of duration of arrhythmia or presence and severity of AF related
- •symptoms) or patients with paroxysmal AF (namely self\-terminating AF
- •usually within 48 hours although it may continue for up to 7 days);
- •2\. Patients with long\-standing persistent AF (for this protocol defined as
- •AF longer than 6 months) or permanent AF (i.e. AF accepted by the
- •patient and by the physician);
- •3\. Patients having known concurrent temporary secondary causes of AF
- •such as alcohol intoxication, pulmonary embolism, hyperthyroidism,
- •pneumonia, hypoxemia, acute pericarditis or myocarditis;
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLOWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-002789-18-ESMENARINI RICERCHE S.P.A241
进行中（未招募）
1 期
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-002789-18-GBMenarini Ricerche S.p.A240
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AFTER TWELVE WEEKS OF TREATMENT, COMPARED PLACEBO AND ETANERCEPT AND TO ASSESS THE SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO ONE YEAR IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASISPER-054-11OVARTIS BIOSCIENSES PERU S.A.,
未知
不适用
A RANDOMIZED, DOUBLED-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FLUTICASONE FUROATE INHALATION POWDER AND FLUTICASONE PROPIONATE INHAATION POWDER IN THE TREATMENT OF ASTHMA IN ADULTS AND ADOLESCENTS NOT CURRENTLY TREATED WITH INHALED CORTICOSTEROIDSPER-076-11GLAXOSMITHKLINE PERU S.A.,119
进行中（未招募）
1 期
A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT) - TURANDOTCrohn’s Disease (CD) and Ulcerative Colitis (UC)MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2012-002030-37-BEPfizer Inc.357